GSK launches prostate drug
October 31, 2003Sales and Marketing
GlaxoSmithKline is to launch Avodart, a new treatment for enlarged prostates, next week into a crowded $1.6 billion global market.The …
Consultants threaten to quit
October 31, 2003More than a quarter of hospital consultants are ready to resign or retire from the NHS if they dont receive …
GSK in running for Pfizer incontinence drug
October 31, 2003Sales and Marketing
GlaxoSmithKline has been tipped to buy a potential blockbuster incontinence drug from Pfizer ahead of the US company's merger with …
Trusts warned over fixing waiting times
October 31, 2003All NHS trusts will have to review how they report waiting times after a spot check found widespread distortion and …
Levitra brings three dimensions to ED market
October 31, 2003Bayer and GlaxoSmithKline's new erectile dysfunction treatment Levitra has been launched in the UK, its first market after receiving European …
Staff shortages holding back NHS progress
October 31, 2003A chronic shortage of staff in some parts of the NHS is holding back improvements to the service, according to …
BMS attempts to distance itself from fraud allegations
October 31, 2003Bristol-Myers Squibb is attempting to draw a line under allegations of fraud and financial misconduct by downgrading earnings as far …
Industry reputation under fire at home and abroad
October 31, 2003Continuing conflict over access to medicines in developing countries and growing distrust of big pharma in domestic markets is threatening …
Germany delay undermines Crestor confidence
October 31, 2003AstraZeneca's cholesterol treatment Crestor has been dealt a serious blow following Germanys withdrawal from a pan-European approval process.Germany, the EU's …
Parliamentary showdown for foundation trust plans
October 31, 2003Health Secretary Alan Milburn has published the final plans for the controversial foundation trusts with the promise that all NHS …
Smallpox vaccine puts Acambis into profit
October 31, 2003Vaccine company Acambis has joined rivals PowderJect and Celltech in the elite group of profitable UK biotech companies.The company recorded …
Shire appoints Emmens as new chief executive
October 31, 2003Matthew Emmens, former head of Merck KGaA's global prescription group, has been appointed as the new Chief Executive of Shire …
Paediatric trials to be mandatory in US
October 31, 2003Plans to make clinical trials mandatory for all drugs intended for children are progressing in the US.The Paediatric Research Equity …
Foundation status offered to 38 more trusts
October 31, 2003A further 38 hospital have been invited to apply for foundation trust status after winning three stars in the recent …
Doubts over pipeline cloud Aventis results
October 31, 2003Aventis may struggle to replace revenue from its ageing blockbusters despite a strong performance in the second quarter, according to …
BMS and Lilly exceed expectations
October 31, 2003Strong sales of established and new products in the second quarter saw both Bristol-Myers Squibb and Eli Lilly beat analysts' …
Smooth transition from old to new for AstraZeneca
October 31, 2003Growth in new products are helping to plug the sizeable gap left by three of AstraZeneca's ageing blockbusters Prilosec (Losec), …
Weak dollar contains Sanofi growth
October 31, 2003The weakness of the US dollar more than halved Sanofi-Synthelabo's earnings in the first half of this year, but disguised …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
